Global Road Construction Projects Insights Report, Q1 2025: Current Pipeline Stands at $3.8 Trillion - Track the Top 20 Projects Per Region
The global road projects pipeline is heavily skewed towards projects in the later stages of development, with the combined value of projects in the pre-execution and execution stages accounting for $2.8 trillion of global pipeline value; a 73% share. Assuming all projects proceed according to their schedules and spending is distributed evenly across the execution stage, annual pipeline expenditure may reach $505.4 billion in 2025.ScopeThe report provides analysis based on the analyst's construction projects showing total project values and analysis by stage and funding for all regions. The top 20 projects per region are listed giving country, stage, value of projects. Ranked listings of the key operators for the sector are also provided showing the leading contractors, consulting engineers and project owners.Reasons to Buy
Gain insight into the development of the road construction sector.
Assess all major projects by value, start date, scope and stage of development globally, for the regions to support business development activities.
Plan campaigns by country based on specific project opportunities and align resources to the most attractive markets.
Key Topics Covered:
Global Overview
North America
Latin America
Western Europe
Eastern Europe
Middle East and North Africa
Sub-Saharan Africa
South-East Asia
North-East Asia
South Asia
Australasia
For more information about this report visit https://www.researchandmarkets.com/r/ysfr8z
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Why Broadcom's (AVGO) AI Momentum Has Goldman Sachs Backing the Stock
Broadcom Inc. (NASDAQ:) is one of the . On July 10, Goldman Sachs analyst James Schneider initiates coverage on the stock with a 'Buy' rating and a price target of $315.00. The firm initiated the U.S. digital semiconductor and electronic design automation software group. 'We believe the AI investment cycle is in a state of transition, with over $350bn in CapEx spent on AI infrastructure. Although monetization has been elusive, we see early signs of incremental revenue and much clearer evidence of cost takeout to justify these investments — and we believe AI CapEx can sustain growth from current levels.' This is what the firm said, particularly for Broadcom: 'Broadcom has a dominant franchise position across several segments of infrastructure software as a result of a long-term M&A strategy. We believe the company is likely to sustain its dominant position in enterprise networking silicon, and will continue to leverage this leadership to drive majority share in custom silicon processors for major US hyperscalers – which should drive AI to comprise over 40% of the company by 2026. A close-up of a complex network of integrated circuits used in logic semiconductors. "At the same time, Broadcom continues to generate steady, growing profitability in its core infrastructure software business. We see the stock's premium valuation as justified by the greater visibility provided by its sole-sourced position at key silicon accounts and the mission-critical nature of its software portfolio.' Broadcom is a technology company uniquely positioned in the AI revolution owing to its custom chip offerings and networking assets. While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
an hour ago
- Yahoo
Will Trump's 200% tariff threat on pharma really materialize?
-- Trump's threat to slap a 200% tariff on pharmaceutical imports, made offhandedly at a cabinet meeting, has sparked a selloff in some drug stocks, but analysts say the number may be more political posturing than economic policy. He floated the figure while saying companies would have 'about a year, a year and a half' to bring production back to the U.S. Bernstein sees that as a crucial buffer. "It is certainly tough to know if 200% tariffs will ever materialize," analysts wrote, adding that such a move is 'probably unlikely.' The scale of the impact, potentially $600 billion in added cost on roughly $200 billion of annual pharmaceutical imports, makes it implausible as a blunt policy tool. Even if enacted, industry response is expected to be swift and significant. Drugmakers like Merck (NSE:PROR) have already been stockpiling in the U.S., with some inventory expected to last through 2027. In the near term, Bernstein sees the threat as manageable. Imports of pharmaceuticals and chemicals spiked in the first quarter, a sign that companies are hedging against future restrictions. GLP-1 drugs, such as those used for diabetes and weight loss, accounted for a substantial portion of that increase. Still, the proposal raises questions about the future of global supply chains and U.S. protectionism. Short-term distortions, such as a widening trade deficit with countries like Ireland, could follow, even as the long-term trend pushes toward more local production. Bernstein downplayed the market's knee-jerk reaction. 'We would be buying the dip,' the analysts said, pointing to Eli Lilly (NYSE:LLY) and Gilead (NASDAQ:GILD) as top picks. While the threat of tariffs isn't trivial, it appears unlikely to materialize at the scale or immediacy suggested, and the industry has time to adjust. Related articles Will Trump's 200% tariff threat on pharma really materialize? Could diffusion models become YouTube and Meta's next growth drivers? What's behind energy drink growth? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
I'm Betting My Future on This Magnificent Canadian Dividend Giant
Written by Kay Ng at The Motley Fool Canada Let's be clear: betting your entire future on a single stock is unwise. Maintaining proper portfolio diversification is always smart. But if I had to pick a single Canadian dividend stock to anchor my long-term portfolio — one with the durability, income, and growth I can rely on for decades — it would be Brookfield Infrastructure Partners (TSX: Here's why this dividend giant has earned my trust — and a prominent place in my retirement plan. Brookfield Infrastructure Partners isn't your average utility. It owns and operates a globally diversified portfolio of high-quality infrastructure assets across utilities, transport, midstream, and data infrastructure. This diversity allows the company to generate consistent, recession-resistant cash flows across economic cycles. At the time of writing, the stock yields a generous 5.2% based on a unit price of $44.89. Even better, the company keeps its payout ratio around 60-70% of funds from operations (FFO) — a level it's maintained for at least a decade. That means the dividend is not only attractive but sustainable. For long-term investors like me, this income can either cover living expenses or be reinvested to accelerate portfolio growth. Even more compelling is Brookfield Infrastructure Partners's track record of dividend growth. The company has increased its cash distribution for 17 consecutive years, with a five-year compound annual growth rate (CAGR) of 6.1% and a 10-year CAGR of 7.7%. These figures far outpace inflation, preserving and growing purchasing power — an essential ingredient for retirement success. BIP targets 6-9% annual organic FFO growth, driven by inflation indexing, GDP growth, and reinvested capital. Roughly 85% of its FFO is backed by regulated or contracted cash flows, with a weighted average contract duration of nine years. That kind of cash-flow visibility is gold in today's unpredictable markets. The company also has a proven ability to recycle capital — buying underperforming or undervalued assets, optimizing them, and then selling them to reinvest in higher-return opportunities. Management's disciplined approach to acquisitions and value creation has helped it deliver superior returns for long-term investors. Over the past decade, has tripled investor capital, delivering an impressive 11.7% annualized return, far ahead of the 8.5% return from the iShares S&P/TSX Capped Utilities Index ETF, a sector benchmark. That kind of outperformance is hard to ignore — and rare among utility stocks. But investors should also know this isn't a sleepy, low-volatility name like Fortis. Brookfield Infrastructure is a capital-intensive, globally active business with more complex operations. Its share price can swing more widely, especially around large acquisitions, asset sales, or macro shocks. For instance, in the last six months, plunged 23% from around a peak of $48 to a trough of $37 per unit. Those with a strong stomach — and a long-term mindset — were rewarded with a buying opportunity. Even now, with units trading near $45, analysts estimate a 15% discount to fair value. Any dip below $40 represents a compelling entry point, in my view. Brookfield Infrastructure Partners isn't just another utility — it's a magnificent dividend machine backed by global assets, reliable income, and a long-term growth strategy that works. While all investments have underlying risks, its combination of yield, operational resilience, and upside potential makes it the kind of stock I'm willing to bet my future on for durable, growing income. The post I'm Betting My Future on This Magnificent Canadian Dividend Giant appeared first on The Motley Fool Canada. Before you buy stock in Brookfield Infrastructure Partners, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Brookfield Infrastructure Partners wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,927.94!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 30 percentage points since 2013*. See the Top Stocks * Returns as of 6/23/25 More reading 10 Stocks Every Canadian Should Own in 2025 [PREMIUM PICKS] Market Volatility Toolkit A Commonsense Cash Back Credit Card We Love Fool contributor Kay Ng has positions in Brookfield Infrastructure Partners. The Motley Fool recommends Brookfield Infrastructure Partners and Fortis. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
